Emerging Biomarkers for Predicting Clinical Outcomes in Patients with Heart Disease

Cardiovascular disease is most frequently caused by the development and progression of atherosclerosis. When coronary arteries are afflicted, and the stenoses caused by atherosclerotic plaques are severe enough, the metabolic supply-and-offer balance is disturbed, leading to myocardial ischemia. If...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2023-01, Vol.13 (1), p.230
Main Authors: Pál, Krisztina, Mănescu, Ion-Bogdan, Lupu, Silvia, Dobreanu, Minodora
Format: Article
Language:English
Subjects:
acute coronary syndrome
Arteries
Arteriosclerosis
Atherosclerosis
Biological markers
Biomarkers
Body mass index
Cardiovascular diseases
Cardiovascular research
Care and treatment
Complications
Congestive heart failure
Coronary artery
coronary artery disease
Diagnosis
Health risks
Heart diseases
heart failure
Ischemia
Medical imaging
Mortality
Myocardial infarction
Myocardial ischemia
Plaques
Prognosis
Review
Thromboembolism
Thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiovascular disease is most frequently caused by the development and progression of atherosclerosis. When coronary arteries are afflicted, and the stenoses caused by atherosclerotic plaques are severe enough, the metabolic supply-and-offer balance is disturbed, leading to myocardial ischemia. If atherosclerotic plaques become unstable and local thrombosis develops, a myocardial infarction occurs. Sometimes, myocardial ischemia and infarction may result in significant and irreversible heart failure. To prevent severe complications, such as acute coronary syndromes and ischemia-related heart failure, extensive efforts have been made for developing biomarkers that would help identify patients at increased risk for cardiovascular events. In this two-part study, we attempted to provide a review of existing knowledge of blood biomarkers that may be used in this setting. The first part of this work was dedicated to conventional biomarkers, which are already used in clinical practice. In the second part, here presented, we discuss emerging biomarkers which have not yet become mainstream.
ISSN:2075-1729
2075-1729
DOI:10.3390/life13010230